These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3032491)

  • 21. Furosemide kinetics and dynamics after kidney transplant.
    Smith DE; Gambertoglio JG; Vincenti F; Benet LZ
    Clin Pharmacol Ther; 1981 Jul; 30(1):105-13. PubMed ID: 7016396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration.
    Sjöström PA; Kron BG; Odlind BG
    Eur J Clin Pharmacol; 1993; 45(2):135-9. PubMed ID: 8223834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
    Ogata H; Kawatsu Y; Maruyama Y; Machida K; Haga T
    Eur J Clin Pharmacol; 1985; 28(1):53-9. PubMed ID: 3987786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and pharmacodynamic effects of furosemide in patients with impaired renal function.
    Traeger A; Stein G; Sperschneider H; Keil E
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):481-6. PubMed ID: 6500766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metamizole-furosemide interaction study in healthy volunteers.
    Rosenkranz B; Lehr KH; Mackert G; Seyberth HW
    Eur J Clin Pharmacol; 1992; 42(6):593-8. PubMed ID: 1623899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biotransformation of furosemide in kidney transplant patients.
    Smith DE; Benet LZ
    Eur J Clin Pharmacol; 1983; 24(6):787-90. PubMed ID: 6350024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of furosemide delivery to its site of action.
    Sjöström PA; Kron BG; Odlind BG
    Clin Nephrol; 1995 Jan; 43 Suppl 1():S38-41. PubMed ID: 7781204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Furosemide kinetics and dynamics in patients with cirrhosis.
    Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
    Rademaker MT; Charles CJ; Nicholls MG; Richards AM
    Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of cimetidine on the absorption and efficacy of orally administered furosemide.
    Rogers HJ; Morrison P; House FR; Bradbrook ID
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):8-11. PubMed ID: 7056605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic dependent disposition of the angiotensin converting enzyme inhibitor, libenzapril.
    Kochak GM; Choi RL; deSilva JK; Reydel-Bax P
    J Clin Pharmacol; 1990 Feb; 30(2):138-43. PubMed ID: 2312764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
    Schuster O; Loew D; Knoell HE
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
    Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
    Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the angiotensin converting enzyme (ACE) inhibitor, captopril, on the cardiovascular, endocrine, and renal responses to furosemide in conscious lambs.
    de Wildt SN; Smith FG
    Can J Physiol Pharmacol; 1997 Apr; 75(4):263-70. PubMed ID: 9196851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of pentopril, an angiotensin converting enzyme inhibitor, and its active metabolite in urine.
    Tipnis V; Rakhit A
    J Chromatogr; 1985 Dec; 345(2):396-401. PubMed ID: 3003138
    [No Abstract]   [Full Text] [Related]  

  • 38. Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide.
    Vree TB; van den Biggelaar-Martea M; Verwey-van Wissen CP
    Br J Clin Pharmacol; 1995 Jun; 39(6):692-5. PubMed ID: 7654491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study on furosemide disposition in man.
    Zhu JB; Koizumi T
    J Pharmacobiodyn; 1987 Aug; 10(8):370-6. PubMed ID: 3694431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).
    Ponto LL; Schoenwald RD
    Clin Pharmacokinet; 1990 May; 18(5):381-408. PubMed ID: 2185908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.